Literature DB >> 6327522

Mechanism of deterioration in renal function in patients with renovascular hypertension treated with enalapril.

W Bender, N La France, W G Walker.   

Abstract

Azotemia produced by converting enzyme inhibition in renovascular hypertension was studied in six patients by measurement of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF). Patients with unilateral renovascular hypertension lowered GFR acutely to 40% of control values at 4 hours, but after 4 days it only returned to 75% of control even though ERPF exceeded control values. Calculated filtration fraction (GFR/ERPF) decreased from 0.31 to 0.19 in 4 hours (p less than 0.05) and remained at 0.20 after 4 days of treatment despite increases in GFR and ERPF. In bilateral renovascular hypertension, neither the decreased GFR nor lowered ERPF induced by enalapril showed any tendency to return toward normal with continued treatment. These data are consistent with selective glomerular efferent arteriolar dilation in response to enalapril and suggest that angiotensin converting-enzyme inhibition interferes with the autoregulatory capacity of the kidney in the presence of severe renovascular hypertension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327522     DOI: 10.1161/01.hyp.6.2_pt_2.i193

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

Review 1.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

Review 2.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 3.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

4.  Evaluation of the safety of enalapril in the treatment of heart failure in the very old.

Authors:  C J O'Neill; S G Bowes; C M Sullens; J P Royston; W B Hunt; M J Denham; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

7.  Enalapril versus triple-drug therapy in the treatment of renovascular hypertension.

Authors:  G P Reams; J H Bauer
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Enalapril induced reversible acute renal failure detected by (99m)Tc-DMSA renal scan in a patient with bilateral renal artery stenosis: a case report.

Authors:  Kianoush Ansari Gilani; Abbas Madani; Nahid Rahimzadeh; Seyedtaher Esfahani; Jamak Modaresi Esfeh
Journal:  Cases J       Date:  2009-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.